{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:56:52Z","timestamp":1789927012346,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T00:00:00Z","timestamp":1277769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ifosfamide 14\u2009g\/m\n                      <jats:sup>2<\/jats:sup>\n                      (with mesna 14\u2009g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Acute grade 3 hematological toxicity was observed in only 13\/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2\u201319 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prolonged 14\u2010day continuous infusion of high\u2010dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer. 2010;55:617\u2013620. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.22596","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T10:56:14Z","timestamp":1277808974000},"page":"617-620","source":"Crossref","is-referenced-by-count":33,"title":["Prolonged 14\u2010day continuous infusion of high\u2010dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma"],"prefix":"10.1002","volume":"55","author":[{"given":"Cristina","family":"Meazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luksch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Podda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Favini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Massimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,25]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1","article-title":"Oxazaphosphorine cytostatics: Past\u2013present\u2013future. Seventh Cain Memorial Award Lecture","volume":"49","author":"Brock N","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073350"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073369"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.V1281615","article-title":"Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide","volume":"12","author":"Dubourg L","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00259-9"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.02.008"},{"key":"e_1_2_5_8_2","first-page":"157","article-title":"Pharmacokinetics of alkylating agents","volume":"17","author":"Lind MJ","year":"1993","journal-title":"Cancer Surv"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80024-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00263897"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90053-8"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.126"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00090-6"},{"key":"e_1_2_5_14_2","first-page":"181","article-title":"A randomized comparison of ifosfamide administered as continuous or short infusion in children with soft tissue sarcoma","volume":"37","author":"Bisogno G","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"e_1_2_5_15_2","first-page":"S174","article-title":"Single agent ifosfamide studies in sarcomas of soft tissue and bone: The MD Anderson experience","volume":"31","author":"Benjamin RS","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.1.170"},{"key":"e_1_2_5_17_2","first-page":"416","article-title":"Phase II trials of ifosfamide with mesna in advanced soft tissue sarcoma patients: A definitive dose\u2013response relationship","volume":"11","author":"Cerny T","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1600"},{"key":"e_1_2_5_19_2","first-page":"22","article-title":"High\u2010dose ifosfamide in the treatment of sarcomas of soft tissue and bones","volume":"23","author":"Demetri GD","year":"1996","journal-title":"Semin Oncol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008279426654"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2378"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008474802882"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2000.18.14.2676","article-title":"Randomized phase III study comparing conventional\u2010dose doxorubicin plus ifosfamide plus recombinant human granulocyte\u2010macrophage colony stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer\/Soft Tissue and Bone Sarcoma Group","volume":"14","author":"Le Cesne A","year":"2000","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199806000-00025"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008311901856"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1438"},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02897261","article-title":"The stability of ifosfamide in aqueous solution and its suitability for continuous 7\u2010day infusion by ambulatory pump","volume":"26","author":"Radford JA","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_5_28_2","volume-title":"NCI common toxicity criteria, version 1. Investigator's handbook: A manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute","author":"National Cancer Institute","year":"1993"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01613216"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<2963::AID-CNCR2820721017>3.0.CO;2-W"},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.annonc.a059118","article-title":"Ambulatory four\u2010day continuous infusion schedule of high\u2010dose ifosfamide with mesna uroprotection and granulocyte colony stimulating factor in advanced solid tumors: A phase I study","volume":"6","author":"Toma S","year":"1995","journal-title":"Ann Oncol"},{"key":"e_1_2_5_32_2","unstructured":"ComandoneA FrustaciS BearzA et al.Efficacy and tolerability of an ifosfamide continuous infusion in soft tissue sarcoma patients. Abstract to CTOS Milan November 1997."},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1054-1"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf004"},{"key":"e_1_2_5_35_2","first-page":"451","article-title":"Studies on the human pharmacokinetics of isophosphoramide","volume":"60","author":"Allen LM","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_5_36_2","first-page":"878","article-title":"Pharmacokinetic and bioavailability of oral ifosfamide","volume":"36","author":"Wagner T","year":"1986","journal-title":"Arzneim Forsch"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.161"},{"key":"e_1_2_5_38_2","first-page":"2945","article-title":"Reduction of ifosfamide toxicity using dose fractionation","volume":"36","author":"Rodriguez V","year":"1976","journal-title":"Cancer Res"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22596","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:52:50Z","timestamp":1700535170000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,25]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/pbc.22596"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22596","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.5606960.5574058","asserted-by":"object"}]},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,25]]}}}